Black Box Warnings
Cardiovascular risk associated with rapid infusion rates
Risk of hypotension and arrhythmias with infusion rates that exceed 150mg/minute of phenytoin sodium equivalents (PE)
Careful cardiac monitoring is needed during and after administering IV administration
These events have also been reported at or below 150mg/minute
Reduce infusion rate or discontinuation may be needed
Cardiovascular collapse
Toxic delirium
Bradycardia
Arrhythmias
Exfoliative dermatitis
Stevens-Johnson
Toxic epidermal necrolysis
Drug rash with eosinophilia and systemic sx
Hepatotoxicity
Thrombocytopenia
Leukopenia
Agranulocytosis
Pancytopenia
Anemia
Purple glove syndrome (IV use)
Cardiovascular risk associated with rapid infusion rates
Risk of hypotension and arrhythmias with infusion rates that exceed 150mg/minute of phenytoin sodium equivalents (PE)
Careful cardiac monitoring is needed during and after administering IV administration
These events have also been reported at or below 150mg/minute
Reduce infusion rate or discontinuation may be needed
Nystagmus
Dizziness
Pruritis
Paresthesia
Headache
Somnolence
Ataxia
Nausea
Tinnitus
Rash
Tremor
Hypotension
Xerostomia
Confusion
Blurred vision
Taste changes
Fever
Injection site reaction
Constipation
Hypokalemia
Fosphenytoin
Phenytoin
Levetiracetam
Lamotrigine
Ethosuximide
Carbamazepine
Topiramate
Oxcarbazepine